Stocks Telegraph
1,161 articles
In a recent update, DT Midstream, Inc. (DTM) received an “Overweight” rating from Robert Kad of Morgan Stanley on September 10, 2026. This positive outlook comes as the stock is currently priced at $129.51, with a potential upside to the analyst’s price target of $170. This change in rating could offer a compelling opportunity for […]
Centerspace (Ticker: CSR) garnered a “Buy” rating from Merrill Ross of Compass Point on September 10, 2026. This endorsement is significant for investors, indicating a positive outlook on the stock’s growth potential, particularly with a price target set at $80 compared to the current trading price of $57.69. Recent Price Action Last week, Centerspace’s stock […]
On September 10, 2026, Piper Sandler analyst Jason Bednar rated The Cooper Companies, Inc. (COO) as Neutral, a notable shift in sentiment that underscores the company’s current market dynamics. With the stock trading at $54.17 and a price target of $86, investors should pay close attention to this development as it suggests a substantial upside […]
On September 10, 2026, Casey’s General Stores, Inc. (NASDAQ: CASY) received an “Outperform” rating from Bobby Griffin at Raymond James, suggesting substantial upside potential in the stock, currently priced at $627.64. This rating could signal an intriguing investment opportunity for both growth-focused and value-seeking investors, especially considering the robust overall performance of the company amid […]
Yum! Brands, Inc. (YUM) recently received an upgraded rating from *Overweight* by Zachary Fadem of Wells Fargo, signaling a positive outlook for the fast-food giant. With the stock currently priced at $145.09 and a price target set at $175, investors may find compelling upside potential in the coming months. This change in sentiment reflects optimism […]
On September 10, 2026, Block, Inc. (Ticker: XYZ) received a notable upgrade from Mark Palmer of StoneX, who has given the stock a “Buy” rating with a price target of $105. This presents a significant upside from its current trading price of $79.40. For investors, this could signal an opportune moment to reconsider the stock’s […]
On September 10, 2026, Synopsys, Inc. (NASDAQ: SNPS) received an upgrade to an Overweight rating from analyst Joe Quatrochi at Wells Fargo, signaling strong upside potential for investors. With a current price of $393.22 and an optimistic price target of $475, this rating reflects confidence in the company’s future growth prospects amid a rapidly evolving […]
Simmons First National Corporation (SFNC) has recently caught the attention of analysts with an upgraded rating from Keefe, Bruyette & Woods. On September 10, 2026, analyst Wood Lay assigned an “Outperform” rating to the stock, setting a price target of $26. This represents a notable upside potential for investors given the current trading price of […]
PACCAR Inc (NASDAQ: PCAR) received an upgraded rating to “Outperform” by analyst Nick Housden of RBC Capital on September 10, 2026. With a newly projected price target of $150, well above its current price of $121.88, this upgrade signals potential upside for investors, adding momentum to PACCAR’s appeal in the commercial vehicle sector. Recent Price […]
Orchestra BioMed Holdings, Inc. (OBIO) has caught the attention of investors following a recent upgrade to a “Buy” rating by analyst Marie Thibault at BTIG. This positive outlook comes alongside a price target set at $10 per share, suggesting a substantial upside potential from the current trading level of $5.45. The implications of this upgrade […]
Investors in Novartis AG (NVS) were greeted with a cautious rating adjustment from HSBC’s Rajesh Kumar, who has placed the stock under a “Hold” rating as of September 10, 2026. The new price target sits at $136, a slight dip from the current price of $137.48. This maneuver highlights the cautious sentiment surrounding the pharmaceutical […]
On September 10, 2026, Meta Platforms, Inc. (ticker: META) garnered attention in the investment community as analysts at JP Morgan upgraded its rating to “Overweight,” setting a price target of $820. This update comes during a tumultuous period for the stock, and it suggests optimism about Meta’s growth trajectory in the coming months. For investors, […]
Herc Holdings Inc. (NYSE: HRI) recently received a noteworthy upgrade from JP Morgan analyst Tami Zakaria, transitioning to an “Overweight” rating with an increased price target of $175. This marks a pivotal moment for the stock, reflecting strong investor optimism and signaling potential gains for those looking to enter or increase their position in the […]
In a recent analysis by Mark Mahaney of Evercore ISI Group, Chewy, Inc. (NASDAQ: CHWY) received an “In-Line” rating as of September 10, 2026, with a price target of $25, suggesting an upside potential relative to its current trading price of $20.75. This rating indicates cautious optimism among analysts, making Chewy a notable consideration for […]
Caterpillar Inc. (CAT) has recently garnered attention after receiving a “Buy” rating from analyst Sergey Glinyanov of Freedom Broker on September 10, 2026, following an impressive earnings performance. With the stock currently priced at $815.56, the analyst’s price target implies a potential upside of approximately 20%, suggesting that investor interest might be rekindling amid a […]
On September 10, 2026, BioCryst Pharmaceuticals, Inc. (NASDAQ: BCRX) was assigned a ‘Sector Perform’ rating by Brian Abrahams of RBC Capital. This change reflects the analyst’s assessment of the company’s current valuation, suggesting limited upside potential given the stock’s prevailing price of $8.81. With a price target of $13, investors may consider the stock an […]
On September 10, 2026, Amgen Inc. (AMGN) received a “Hold” rating from HSBC analyst Morten Herholdt, reflecting a more cautious stance on the pharmaceutical giant’s stock moving forward. This rating comes as Amgen’s shares trade at $391.27, suggesting a potential upside to the analyst’s price target of $445. For investors, this rating signals a pause […]
UGI Corporation (NYSE: UGI) has recently captured the attention of investors after Jefferies analyst Julien Dumoulin-Smith issued a Buy rating on the stock with a price target of $43. This optimistic view translates into an approximately 12% upside potential from UGI’s current trading price of $38.54, positioning it as an attractive investment opportunity amid fluctuating […]
On September 9, 2026, Faisal Khurshid from Jefferies initiated coverage on Summit Therapeutics Inc. (SMMT), issuing a ‘Buy’ rating with a target price of $25. Given its current trading price of $17.54, this suggests significant upside potential for investors. As the company navigates a complex market landscape, understanding the factors influencing its performance becomes essential […]
In a recent analysis, Morgan Stanley analyst Ronald Kamdem upgraded Lineage, Inc. (LINE) to an “Overweight” rating on September 9, 2026. This upgrade is significant for investors as it not only reflects confidence in the company’s future performance but also positions the stock with a target price of $47, suggesting a potential upside from its […]
Westlake Corporation (WLK) recently received a “Market Perform” rating from John McNulty at BMO Capital, effective September 9, 2026, with analysts suggesting a price target of $96. This rating reflects caution, indicating that while the stock may hold its ground in the near term, investors should prepare for modest upside potential from its current price […]
Waters Corporation (WAT) has recently garnered attention from analysts, with Doug Schenkel of UBS upgrading the stock to a “Buy” on September 9, 2026. This recommendation comes with a price target of $490, representing a notable upside potential from its current trading price of $402.91. For investors keeping a close eye on the life sciences […]
Vulcan Materials Company (VMC) recently received an “Underweight” rating from Wells Fargo, issued by analyst Timna Tanners on September 9, 2026. This downgrade comes amid shifting market dynamics and raises important considerations for investors engaged in the construction materials sector. The downgrade indicates a cautious outlook for the stock, prompting investors to reconsider their positions […]
In a pivotal shift for Sagimet Biosciences Inc. (SGMT), analyst Eliana Merle of Barclays upgraded the company’s rating to Overweight on September 9, 2026, signaling renewed confidence in the biotech firm’s growth prospects. This rating comes against a backdrop of mixed market performance and fluctuating investor sentiments but underscores an optimistic outlook, particularly with a […]
